The size of the Middle East & Africa Superdisintegrants Market was calculated at USD 28.74 million in 2022. It is further estimated to be growing at a CAGR of 9.57% and worth USD 45.39 million by 2027.
The factors such as the increasing prevalence of cardiovascular diseases and the growing adoption of orally disintegrants tablets are driving the superdisintegrants market in MEA. Also, the rising emergence of new superdisintegrants for the pharmaceutical industry boosts market growth. In addition, the shifting focus of pharmaceutical manufacturing to the emerging countries such as UAE, Saudi Arabia, and South Africa are expanding the MEA regional market growth.
Other factors such as increasing awareness among the people and the growing healthcare expenditure accelerate the demand for the superdisintegrants market. In addition, the technological advancement in the healthcare sector and the increasing adoption of novel excipients support market growth. When solid dosage forms, such as capsules or tablets, are submerged in liquid, superdisintegrants are added to help them disintegrate. Because of this advantage, superdisintegrants are widely used to produce disintegrating oral formulations, increasing market demand for superdisintegrants. In addition, a growing percentage of pediatric patients and the elderly population cannot take solid medications. Therefore, these compounds are utilized in drug-loaded films to improve performance and maintain high drug content homogeneity by increasing viscosity.
On the other hand, the increasing use of orally disintegrating tablets in the pharmaceutical and nutraceutical industries to treat dysphagia and other diseases is projected to contribute to market growth during the forecast period. Further, increasing investments and funding by the government in healthcare infrastructure and research and development activities are expected to provide lucrative growth opportunities for market growth.
However, safety and the quality concerns associated with the superdisintegrants limit the market growth.
This research report on the Middle East and Africa superdisintegrants market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Area:
The MEA is anticipated to grow significantly in the super disintegrants market during the forecast period. The regional market growth is driven by the increasing number of Pediatric patients, the rising prevalence of Alzheimer’s and cardiovascular diseases, and the supportive government policies and investments. Further, the presence of key market players and the implementation of various market strategies such as collaborations, mergers, and acquisitions are strengthening the MEA regional market growth.
South Africa is likely to account for a significant market share during the forecast period due to the advancing healthcare sector, growing geriatric population, and high healthcare expenditure.
UAE is a significant country for MEA regional market growth. The advancing healthcare sector, availability of funding for research and development activities, and local collaboration for product development is are fuelling the market growth.
On the other hand, Saudi Arabia is most likely to record a considerable share in the market during the forecast period. The factors such as supportive government initiatives, increasing prevalence of patient population, growing awareness, and Improving healthcare infrastructure contribute to the market growth.
KEY MARKET PLAYERS:
Companies playing a significant role in the MEA Superdisintegrants Market studied in this report are Ashland, BASF SE, FMC Corporation, JRS Pharma, DFE Pharma, Roquette, The Dow Chemical Company, Asahi Kasei Corporation, Nippon Soda Co., and Huber Corporation.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.2 Natural Superdisintegrants
5.1.3 Synthetic Superdisintegrants
220.127.116.11 Modified Starch
18.104.22.168 Modified Cellulose
22.214.171.124 Ion Exchange Resins
126.96.36.199 Calcium Silicates
5.1.5 Y-o-Y Growth Analysis, By Product Type
5.1.6 Market Attractiveness Analysis, By Product Type
5.1.7 Market Share Analysis, By Product Type
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
5.3 Therapeutic Area
5.3.2 Gastrointestinal diseases
5.3.3 Neurological diseases
5.3.5 Infectious Diseases
5.3.6 Cardiovascular Diseases
5.3.7 Haematological diseases
5.3.8 Inflammatory Diseases
5.3.9 Y-o-Y Growth Analysis, By Therapeutic Area
5.3.10 Market Attractiveness Analysis, By Therapeutic Area
5.3.11 Market Share Analysis, By Therapeutic Area
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product Type
220.127.116.11 By Application
18.104.22.168 By Therapeutic Area
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product Type
188.8.131.52 By Application
184.108.40.206 By Therapeutic Area
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Product Type
22.214.171.124 By Application
126.96.36.199 By Therapeutic Area
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1.2 Product Type Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 BASF SE
8.3 FMC Corporation
8.4 JRS Pharma
8.5 DFE Pharma
8.7 The Dow Chemical Company
8.8 Asahi Kasei Corporation
8.9 Nippon Soda Co.
8.10 Huber Corporation
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.